Some bullish analysts see faster approval timelines and emerging market strength driving Pfizer’s future beyond consensus, projecting up to US$15.1 billion earnings by 2028. The optimism here is much higher than mainstream expectations, so opinions vary widely on how much recent deals and regulatory clarity truly change the story. Consider these differences as you explore what could lie ahead for Pfizer. If you're looking for income, give this blue chip stock a closer look. Pfizer's future is not guaranteed to be golden in the years ahead, but it certainly has potential. Pfizer PFE stock forecast 2025 could benefit from US healthcare policy stability; sector reforms and drug pricing negotiations remain pivotal risk factors shaping forward P/E valuations.
